Alzheimer’s drug failure sends Lundbeck’s shares crashing

pharmafile | September 23, 2016 | News story | Medical Communications, Research and Development Alzheimer's, Lundbeck, cultural failings 

Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of Alzheimer’s.

The company saw its shares fall by 17% as a result of the news, its biggest drop in four years. The study could not reproduce the promising findings of earlier studies, with the drug failing to improve symptoms of the disease according to the Alzheimer’s Disease Assessment Scale-cognitive (ADAS-cog).

Idalopirdine promotes a chemical the brain uses to process thought by blocking a cell receptor called 5-HT6. The Copenhagen-based company has two additional late-stage studies ongoing, with results expected early next year.

Matt Fellows

Related Content

Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug

Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US …

Eli Lilly to seek FDA approval for experimental Alzheimer’s drug

Eli Lilly plans to seek accelerated FDA approval for its experimental Alzheimer’s drug donanemab, announcing …


Evonik and Cassava Sciences enter supply agreement for Alzheimer’s drug candidate

Evonik has entered into an agreement to supply Cassava Sciences with large-scale, clinical-grade quantities of …

Latest content